Literature DB >> 12451080

Pharmaceutical cost containment with reference-based pricing: time for refinements.

Sebastian Schneeweiss1, Malcolm Maclure, Colin Dormuth, Jerry Avorn.   

Abstract

Mesh：

Year:  2002        PMID： 12451080      PMCID： PMC134136     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  21 in total

Review 1.  The Medicare prescription drug benefit: how will the game be played?

Authors:  H A Huskamp; M B Rosenthal; R G Frank; J P Newhouse
Journal:  Health Aff (Millwood)       Date:  2000 Mar-Apr       Impact factor: 6.301

2.  What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?

Authors:  S Schneeweiss; O Schöffski; G W Selke
Journal:  Health Policy       Date:  1998-06       Impact factor: 2.980

3.  Fundholding general practices.

Authors:  A Coulter
Journal:  BMJ       Date:  1992-02-15

Review 4.  Consequences of implementing a drug budget for office-based physicians in Germany.

Authors:  O Schöffski
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

5.  Withdrawing payment for nonscientific drug therapy. Intended and unexpected effects of a large-scale natural experiment.

Authors:  S B Soumerai; D Ross-Degnan; S Gortmaker; J Avorn
Journal:  JAMA       Date:  1990-02-09       Impact factor: 56.272

6.  Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing".

Authors:  J Avorn; S B Soumerai
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

7.  Scientific versus commercial sources of influence on the prescribing behavior of physicians.

Authors:  J Avorn; M Chen; R Hartley
Journal:  Am J Med       Date:  1982-07       Impact factor: 4.965

8.  Is prior authorization of topical tretinoin for acne cost effective?

Authors:  S R Feldman; A B Fleischer; G J Chen
Journal:  Am J Manag Care       Date:  1999-04       Impact factor: 2.229

9.  Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

Authors:  S B Soumerai; J Avorn; D Ross-Degnan; S Gortmaker
Journal:  N Engl J Med       Date:  1987-08-27       Impact factor: 91.245

10.  Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.

Authors:  S B Soumerai; D Ross-Degnan; J Avorn; T j McLaughlin; I Choodnovskiy
Journal:  N Engl J Med       Date:  1991-10-10       Impact factor: 91.245
View more
  4 in total

1.  Reference-based refinements.

Authors:  John Graham
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

2.  Does knowledge of medication prices predict physicians' support for cost effective prescribing policies.

Authors:  Jennifer M Polinski; Malcolm Maclure; Blair Marshall; Alan Cassels; Jessica Agnew-Blais; Amanda R Patrick; Sebastian Schneeweiss
Journal:  Can J Clin Pharmacol       Date:  2008-07-19

3.  Potential savings of harmonising hospital and community formularies for chronic disease medications initiated in hospital.

Authors:  Lauren Lapointe-Shaw; Hadas D Fischer; Alice Newman; Ava John-Baptiste; Geoffrey M Anderson; Paula A Rochon; Chaim M Bell
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

4.  First-line first? Trends in thiazide prescribing for hypertensive seniors.

Authors:  Steve Morgan; Kenneth L Bassett; James M Wright; Lixiang Yan
Journal:  PLoS Med       Date:  2005-04-26       Impact factor: 11.069
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.